Decoy (DCOY) news
Recent news
Decoy Therapeutics stockholders elect Patricia Gauthier to board of directors
On July 14, 2026, Decoy Therapeutics Inc. (Nasdaq: DCOY) held its Annual Meeting of Stockholders, during which Patricia Gauthier, MBA, LL.B., was elected as a Class II director. The nomination of Gauthier, a seasoned biopharma executive, was announced by the company on June 3, 2026. Her election…
AInvest Wire · Jul 15, 2026Decoy Therapeutics - files for resale of up to 3.77 mln shares - SEC filing
Decoy Therapeutics Inc. has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) to register the resale of up to 3.77 million shares of its common stock, according to a recent SEC filing . The filing, dated June 15, 2026, is categorized under Form S-1, which is…
AInvest Wire · Jul 10, 2026Decoy Therapeutics, Inc. announces up to $21 million private placement financing
AInvest Wire · Jun 27, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.